En Es
Categories

Industry News

Thermo Fisher Scientific to Acquire QIAGEN N.V.

By Labmedica International staff writers
05 Mar 2020

IllustrationThermo Fisher Scientific Inc. (Waltham, MA, USA) has announced that it plans to acquire QIAGEN N.V. (Venlo, Netherlands), a provider of molecular diagnostics and sample preparation technologies. Thermo Fisher's boards of directors and the managing board of QIAGEN have unanimously approved Thermo Fisher's proposal to acquire QIAGEN.

QIAGEN provides life science and molecular diagnostic solutions and its sample preparation technologies are used to extract, isolate and purify DNA, RNA and proteins from a wide range of biological samples. The company's assay technologies are then used to amplify and enrich these biomolecules to make them readily accessible for analysis. In addition, QIAGEN's instruments can be used to automate these workflows, while its bioinformatics systems provide customers with relevant, actionable insights.

Thermo Fisher has built leading specialty diagnostics capabilities, including allergy and autoimmunity, transplant diagnostics and clinical oncology testing. QIAGEN has a strong presence in molecular diagnostics with a product portfolio focused on infectious disease and other growth opportunities. The combined company will accelerate the development of higher-specificity, faster and more comprehensive tests that may improve patient outcomes and reduce the cost of care. For life sciences researchers, QIAGEN's innovative sample preparation, assay and bioinformatics technologies are complementary to Thermo Fisher's genetic analysis and biosciences capabilities. As an example, with an expanded portfolio, Thermo Fisher will be able to provide research customers with broader capabilities to accelerate discovery and enable scientific breakthroughs.

"We are excited to bring together our complementary offerings to advance our customers' important work, from discovery to diagnostics," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging healthcare needs. For shareholders, we expect the transaction to be immediately accretive and to generate significant cost and revenue synergies. We look forward to welcoming QIAGEN's employees to Thermo Fisher and are excited about the new opportunities we'll have to advance precision medicine through new molecular diagnostics and improved life sciences workflows."

"Our vision at QIAGEN has always been to make improvements in life possible with our differentiated Sample to Insight molecular testing solutions," said Thierry Bernard, interim chief executive officer of QIAGEN N.V. and senior vice president, head of the molecular diagnostics business area. "This strategic step with Thermo Fisher will enable us to enter a promising new era and will give our employees the opportunity to have an even greater impact. The combination is designed to deliver significant cash value to our shareholders, while enabling us to accelerate the expansion of our solutions to provide customers worldwide with breakthroughs that advance our knowledge about the science of life and improve health outcomes."

Related Links:
Thermo Fisher Scientific Inc.
QIAGEN N.V.




E-mail Print
FaceBook Twitter Google+ Linked in

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrated systems for sequencing, flow cytometry and real-time, digital and end point PCR—from sample prep to data analysis. The company’s products and services help increase productivity and efficiency by providing rapid and accurate results for customers in the research, clinical and applied markets.
More info

More articles about THERMO FISHER SCIENTIFIC

03 Oct 2017
Thermo LC-MS Solutions Receive ANVISA Registration in Brazil
Thermo Fisher Scientific’s liquid chromatography mass spectrometry (LC-MS) in vitro diagnostic (IVD) systems, which enable the quantitation of analytes in complex matrices, have received registration by Brazil’s National Health Surveillance Agency (ANVISA), allowing clinical laboratories in the country to now screen and quantify drugs efficiently.
Read More

Additional news

23 Jun 2020
Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience
Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online.
Read More
12 Jun 2020
Global Magnetic Resonance Imaging (MRI) Market to be driven by Advancements in Medical Diagnostics
The global magnetic resonance imaging (MRI) market was valued at USD 5.90 billion in 2017 and is projected to register a CAGR of 5.2% from 2018 to 2026, driven by increased demand for MRI equipment across the world due to a substantial rise in incidence of disorders related to spine, neurology, orthopedic, cardiovascular, head and neck, and abdominal and prostate.
Read More
30 May 2020
MEDICAL FAIR ASIA 2020 Set to Take Place in Singapore from 9-11 December 2020
MEDICAL FAIR ASIA 2020 is set to take place in Singapore from 9-11 December 2020 at Marina Bay Sands, with the exhibition featuring the latest medical technology and innovations, and healthcare equipment and supplies.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
17 Apr 2020
ECR 2020 to Go Ahead as Online Congress on July 15-19, 2020
In view of the ongoing spread of COVID-19 across the world and its growing global impact, the board of directors of the European Society of Radiology (Vienna) has decided not to hold an onsite European Congress of Radiology (ECR) in 2020. Instead, ECR 2020 will go ahead as an online congress to ensure a safe experience for its members, partners, staff and the general public.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
01 Apr 2020
SymphonyAI Acquires TeraRecon
SymphonyAI Group (Los Altos, CA, USA), an operating group of leading business-to-business artificial intelligence (AI) companies, has acquired TeraRecon (Durham, NC, USA), an advanced visualization and AI solution provider for medical imaging.
Read More
23 Mar 2020
Artificial Intelligence-Based Methods to Cut MRI Read Times Receives USD 250K Grant
 Research to detect and predict blocked arteries and cardiovascular risk using knee MRI images conducted by Chun Yuan, Ph.D., Professor of Radiology and Bioengineering and Vice Chair for Global Affairs at the University of Washington (Seattle, WA, USA) has been recognized and awarded a grant by the American Heart Association’s (AHA) Institute for Precision Cardiovascular Medicine (Dallas, TX, USA).
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions